Global Surufatinib Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Surufatinib market size was valued at US$ 32.82 million in 2025 and is forecast to a readjusted size of US$ 67.39 million by 2032 with a CAGR of 5.8% during review period.
.In 2025, global surufatinib production reached approximately 12.6 million units.Surufatinib is an oral small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of neuroendocrine tumors (NETs). It exerts its effects by simultaneously inhibiting multiple signaling pathways, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and colony-stimulating factor-1 receptor (CSF-1R), thereby providing dual anti-angiogenic and tumor immune-modulating activities, which suppress tumor growth and the immunosuppressive tumor microenvironment. Surufatinib is characterized by a multi-target synergistic mechanism, convenient oral administration, and broad-spectrum antitumor activity, making it clinically valuable in the treatment of advanced neuroendocrine tumors.
Surufatinib, as a multi-target tyrosine kinase inhibitor (TKI), operates within a relatively niche yet growing segment of the neuroendocrine tumor (NET) treatment market. With the increasing detection of NETs due to improved diagnostic methods and the advancement of precision medicine, the demand for targeted therapies continues to rise, providing a stable market foundation for surufatinib.From a competitive landscape perspective, targeted therapies and mTOR inhibitors such as Sunitinib and Everolimus currently dominate the market. However, surufatinib, with its multi-target mechanism acting on VEGFR, FGFR, and CSF-1R, as well as its differentiated advantage in modulating the tumor immune microenvironment, demonstrates competitive potential in specific patient populations.On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, although treatment options for neuroendocrine tumors remain relatively limited, the continuous development of new targeted therapies and immunotherapy regimens is gradually intensifying competition. Therefore, the future market performance of surufatinib will depend on its progress in expanding indications (such as additional NET subtypes or other solid tumors), developing combination treatment strategies, and accumulating real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and cost.
This report is a detailed and comprehensive analysis for global Surufatinib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Surufatinib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Surufatinib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Surufatinib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Surufatinib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Surufatinib
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Surufatinib market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include HUTCHMED, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Surufatinib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Hospital
Retail Pharmacy
Online Pharmacy
Market segment by Application
Neuroendocrine Tumor
Anti-angiogenic Therapy
Tumor Immune Microenvironment Modulation
Others
Major players covered
HUTCHMED
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Surufatinib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Surufatinib, with price, sales quantity, revenue, and global market share of Surufatinib from 2021 to 2026.
Chapter 3, the Surufatinib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Surufatinib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Surufatinib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Surufatinib.
Chapter 14 and 15, to describe Surufatinib sales channel, distributors, customers, research findings and conclusion.